SCHEMBL5756492

SCHEMBL5756492

Cc1ccc(C(=O)N[C@@H](C)c2ccccc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.57
CNR1 P21554 3/20 0.54
CNR2 P34972 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.49
ATM Q13315 1/20 0.49
NOTUM Q6P988 1/20 0.49
GPR139 Q6DWJ6 1/20 0.48
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
ACACB O00763 2/20 0.46
LIPG Q9Y5X9 1/20 0.43
PTGER4 P35408 2/20 0.43
PTGDR Q13258 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756526 1.00 ELANE (0.57) ELANECNR1CNR2L3MBTL1ATM
SCHEMBL5757651 0.91 ELANE (0.54) ELANECNR1CNR2L3MBTL1ATM
SCHEMBL5759226 0.87 ELANE (0.57) ELANEL3MBTL1ATMNOTUMGPR139
SCHEMBL5931076 0.85 ELANE (0.56) ELANECNR1CNR2L3MBTL1ATM
SCHEMBL561192 0.84 CNR1 (0.50) ELANECNR1CNR2L3MBTL1ATM
SCHEMBL31490266 0.84 CNR1 (0.50) ELANECNR1CNR2L3MBTL1ATM
SCHEMBL5440445 0.84 PLA2G10 (0.51) CNR1CNR2L3MBTL1ATMNOTUM
SCHEMBL5756676 0.84 ELANE (0.60) ELANENOTUMGPR139KDM4ESMN1; SMN2
SCHEMBL5758193 0.83 ELANE (0.58) ELANEL3MBTL1ATMNOTUMKDM4E
SCHEMBL11894963 0.83 CNR1 (0.51) ELANECNR1CNR2L3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885CNR1 2232/4885CNR2 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.